IP Verse

Binding Molecules For Bcma And Cd3

Patent No. EP2780375 (titled "Binding Molecules For Bcma And Cd3") was filed by Amgen on Nov 15, 2012. The application was issued on Sep 11, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (9)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
SANOFIJun 12, 2020HOFFMANN EITLE
JAMES POOLEJun 11, 2020CARPMAELS & RANSFORD
MATHYS & SQUIREJun 11, 2020MATHYS & SQUIRE
REGENERON PHARMACEUTICALSJun 11, 2020CARPMAELS & RANSFORD
TENEOBIOJun 10, 2020HOFFMANN EITLE
PFIZERMay 4, 2020PFIZER
JANSSEN BIOTECHApr 14, 2020CARPMAELS & RANSFORD
ABBVIEMar 6, 2020KONIG SZYNKA TILMANN VON RENESSE DUSSELDORF
ABBVIEMar 6, 2020KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORF

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2780375

AMGEN
Application Number
EP12805432A
Filing Date
Nov 15, 2012
Status
Revoked
May 31, 2024
Publication Date
Sep 11, 2019
External Links
Slate, Register , Google Patents